Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • PharmaTutor
    30 November 2011

    Isolation And Molecular Characterization Of Xylanase Enzyme From Soil

    About Author:
    E.Ashwini
    Microbiologist  In  Institute Of Health Systems, Hyderabad
    M.Sc Microbiology From Osmania University.

    ABSTRACT
    The purpose of this study was to determine the effect of some cultural conditions on the xylanase enzyme production by two Isolated Species from the industrial soiland to investigate its potential to produce xylanase utilizing tomato pomace as a substrate. Xylanase activity was detected using the Dinitrosalicylic acid assay method.
    The Alkalophilic bacteria isolated from the industrial soil, secreats extra cellular xylanases when grown in liquid media supplemented with eithter rice bran, grass, corn cob, or sugar baggage as a carbon sources (which were treated with 2N NaoH for removing the cellulose from these substrates). The two bacteria belonging to the species Sporo lactobacilli and Acrobacter respectively shows the high enzyme activity at high temperatures 50 degree C and 60 degree C and high enzyme activity was found at pH 8 and pH 9 for two organisms. The extra cellular enzyme has an apparent molecular weight of 66 KD & 67KD for both the organism respectively, as determined by SDS-PAGE. The purified enzyme has two peptides and was conformed by Zymogram analysis. The species sporo lactobacilli show high enzyme activity of 4.7 U/ml and the species Acrobacter shows the enzyme activity of 7.46 U/ml.

  • 30 November 2011
    Farewell time for world’s largest selling chartbuster pharmaceutical brand Lipitor®: What next after November 30, 2011

    About Authors:
    Dr. Amit Gangwal,
    Smriti College of Pharmaceutical Education,
    Indore

    Introduction
    Lipitor® is the best-selling drug ever, accounting for $106 billion sales over the last decade. Two generic drug manufacturers are ready to compete starting December 1, 2011. Watson Pharmaceuticals is making a generic version authorized by Pfizer under a profit-sharing agreement. Pending federal approval, Ranbaxy Laboratories also plans to sell a generic version. It is noteworthy that when a drug’s patent protection expires, the federal law permits only limited generic competition in the first six months1.

  • 15 September 2011
    AICTE Sponsored Quality Improvement Programme 2011 on Nanotechnology Based Drug Delivery Systems

    BIRLA INSTITUTE OF TECHNOLOGY

  • 7 September 2011
    New twist in diabetes drugs could reduce life-threatening side effects

    Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter, Fla reported that they have created prototype drugs having powerful anti-diabetic effects.

  • 7 September 2011
    Deficiencies of LH and low dose HCG can improve the outcome of IVF

    A new study suggests that women with deficiencies of luteinizing hormone (LH) and low dose human chorionic gonadotropin (hCG) can improve the outcome of in vitro fertilization (IVF).

  • 5 September 2011
    AstraZeneca announced Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN)

    AstraZeneca announced top-line results from SATURN. SATURN was designed to measure the impact of CRESTOR (rosuvastatin) 40 mg and atorvastatin 80 mg on the progression of atherosclerosis in high risk patients.

  • 5 September 2011
    New Studies suggests which is more relevant to reduce risk of venous thromboembolism: Estradiol transdermal system or estrogen contraceptive pills

    A New studies suggested a new hormonal therapy to reduce risk of venous thromboembolism than oral estrogen-only hormone therapy agents (contraceptive pills). In this study they compared Estradiol transdermal system with oral estrogen hormone therapy.

  • 4 September 2011
    Sanofi Aventis Acquire Universal Medicare’s Nutraceutical Business

    Aventis Pharma Limited (part of the Sanofi Group) announced on 24th August, 2011 that it has entered into a definitive agreement to acquire Universal Medicare Private Limited’s business of marketing and distribution of branded nutraceutical formulations in India. Also, approximately 750 commercial employees will transition to Aventis Pharma Ltd. The transaction has been approved by the Boards of Directors of both companies.

  • 3 September 2011
    Eli Lilly India (Lilly) and Lupin Limited (Lupin) Announced Strategic Collaboration to Help Fight the Battle Against Diabetes

    Eli Lilly India (Lilly) and Lupin Limited (Lupin) announced on 29th July, 2011 that they have entered into a strategic collaboration to promote and distribute Lilly’s Huminsulin range of products, including Huminsulin RTM, Huminsulin NPHTM, Huminsulin 50/50TM, Huminsulin 30/70TM and Humapen Ergo II. Lupin’s India formulations business will promote and distribute the range of products in India and Nepal, virtually doubling the number of sales representatives behind the diabetes care product.

  • 2 September 2011
    Lupin Receives Final Approval to Market Generic Ultram® ER from US FDA

    Lupin Pharmaceuticals, Inc. (LPI) announced on 29th aug, 2011 that it has received final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Extended-Release Tablets, 100, 200 and 300 mg strengths. Lupin will begin shipping its Tramadol ER shortly.

Subscribe to Pharma News